2023: First SOD1 ALS Therapy

On This Day in Health: April 25, 2023

On April 25, 2023, the U.S. Food and Drug Administration granted accelerated approval to Qalsody, or tofersen, for adults with amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. The decision introduced a treatment directed at a genetic cause of this progressive neurological disease. It applied to a small, defined subset of the ALS population, making genetic testing important to identifying the relevant patients. The milestone was not an approval for every form of ALS or proof that the disease had been cured. Its significance lay in a new biological approach and the particular type of evidence used to support access.

ALS damages the nerve cells that control voluntary muscles, affecting functions such as walking, speaking, swallowing and breathing. In SOD1-associated disease, mutations can lead to harmful effects of the SOD1 protein. Tofersen is an antisense oligonucleotide designed to bind to SOD1 messenger RNA and reduce production of that protein. This links an identified genetic mechanism with an intervention at the RNA level. The medicine is administered into cerebrospinal fluid through a spinal injection performed by an experienced healthcare professional. Its route and target distinguish it from an ordinary oral symptom medicine and reflect the challenges of reaching the nervous system with a molecularly directed treatment.

The randomized, double-blind clinical study included 108 patients assigned to tofersen or placebo. Investigators measured clinical function as well as biological markers. The primary functional outcome at twenty-eight weeks did not show a statistically significant difference in the principal analysis population. The approval instead relied on a reduction in plasma neurofilament light, a marker associated with nerve-cell injury, considered reasonably likely to predict clinical benefit. This distinction is central to the historical account. A change in a biomarker can provide meaningful evidence about disease processes, but it should not be described as the same thing as a demonstrated improvement in survival or a confirmed functional benefit at that trial endpoint.

April 25 illustrates both the promise of genetic targeting and the responsibilities of accelerated approval. Further study was required to confirm clinical benefit, while neurological adverse effects and the burdens of administration remained part of care. The development also shows how a rare subgroup can guide research toward an intervention that would not be expected to apply equally to all patients with a similar diagnosis. The anniversary’s lasting importance is the approval of a medicine aimed at a specific genetic mechanism in ALS, accompanied by a clear separation between the biological effect that supported the decision and the clinical outcomes that still required confirmation. That precision makes the milestone more informative without diminishing its significance.